Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The in vivo nonclinical studies in rodents have demonstrated that vortioxetine modulates serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Bang-Andersen et al, 2011
In the citing paper
“The antidepressant vortioxetine, developed by Lundbeck and Takeda and approved in 2013, is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a 5-HT 1B receptor partial agonist, a 5-HT 1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011) with a good tolerability and long-term safety profile and no evidence of sexual dysfunction as a side effect.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bang-Andersen et al., 2011
In the citing paper
“Vortioxetine (Lu AA21004) is an antidepressant that acts as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [88]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines
Guram, A. S., Rennels, R. A., & Buchwald, S. L. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199513481 · Cited by 1,070
Louie, J., & Hartwig, J. F. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00605-c · Cited by 914
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Research works printed but not linked: 3
- Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
- Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
- Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page
Cited by
Items 201–300 of 628
Findling, R. L., Robb, A. S., DelBello, M. P., Huß, M., McNamara, N., Sarkis, E. H., Scheffer, R. E., Poulsen, L. H., Chen, G., Lemming, O. M., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0047 · Cited by 25
“Vortioxetine is a multimodal-acting antidepressant that acts as a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, as well as a 5- HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the 5-HT transporter in vitro (Bang-Andersen et al. 2011; Mork et al. 2012; Westrich et al. 2012).”
BackgroundNicola, M. D., Pepe, M., Panaccione, I., Moccia, L., Dattoli, L., Molinaro, M., Sani, G., Janiri, L., & McIntyre, R. S. (2020) · CNS Spectrums · doi:10.1017/s109285292000173x · Cited by 22
de Oliveira, C. M., de Smedt-Peyrusse, V., Morael, J., Vancassel, S., Capuron, L., Gaudout, D., Pourtau, L., & Castanon, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122155 · Cited by 18
Veldman, E. R., Svedberg, M. M., Svenningsson, P., & Lundberg, J. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.02.011 · Cited by 23
Freeman, M. P., Cheng, L. J., Moustafa, D., Davies, A. C., Sosinsky, A. Z., Wang, B. H., Petrillo, L. F., Hogan, C. S., & Cohen, L. S. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900407 · Cited by 54
Liu, X., Sun, Y., Zhang, C., Zhang, X., Zhang, Y., Wang, T., Ma, Y., Wang, H., Su, Y., Li, J., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108468 · Cited by 22
“Among these actions, SERT inhibition and 5-HT1A agonism together help to increase 5-HT concentration in the synaptic cleft and contribute to vortioxetine antidepressant effects (Bang-Andersen et al., 2011; Connolly and Thase, 2016; Stahl, 2015).”
BackgroundHatherall, L. C., Sánchez, C., & Morilak, D. A. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw105 · Cited by 21
Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
Findling, R. L., Robb, A. S., DelBello, M. P., Huß, M., McNamara, N., Sarkis, E. H., Scheffer, R. E., Poulsen, L. H., Chen, G., Lemming, O. M., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0155 · Cited by 23
“526 transporter in vitro (Bang-Andersen et al. 2011; Mork et al. 2012; Westrich et al. 2012).”
Witt, N. A., Lee, B., Ghent, K., Zhang, W. Q., Pehrson, A., Sánchez, C., & Gould, G. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00386 · Cited by 19
Król, M., Ślifirski, G., Kleps, J., Ulenberg, S., Belka, M., Bączek, T., Siwek, A., Stachowicz, K., Szewczyk, B., Nowak, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052329 · Cited by 21
“H) and 6c (R = -OCH3, R1 = H) had a cLogP value of 4.32 and 4.30, respectively, which can be compared to the cLogP value of 4.26 [30] of Vortioxetine, a well-known antidepressant of the SSRI/5-HT1A class.”
BackgroundInfluentialAkki, M., Reddy, D. S., Katagi, K. S., Kumar, A., Devarajegowda, H. C., Sunitha Kumari, M., Babagond, V., Mane, S., & Joshi, S. D. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133452 · Cited by 21
Qin, M., Qiao, H., Yuan, Y., & Shao, Q. (2018) · Analytical Methods · doi:10.1039/c7ay02642k · Cited by 21
Watanabe, K., Fujimoto, S., Marumoto, T., Kitagawa, T., Ishida, K., Nakajima, T., Moriguchi, Y., Fujikawa, K., & Inoue, T. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s340281 · Cited by 21
Oosterhof, C. A., Mansari, M. E., & Blier, P. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.006 · Cited by 20
“Notably, while paroxetine and fluoxetine do not have appreciable affinity for 5-HT1B autoreceptors, in vitro and in vivo data suggest that vortioxetine and asenapine both act as partial agonists at this receptor subtype (Bang-Andersen et al., 2011; El Mansari et al., in press; Shahid et al., 2009).”
BackgroundZeppelin, T., Ladefoged, L. K., Sinning, S., & Schiøtt, B. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.030 · Cited by 20
Emam, A. M., Saad, M. A., Ahmed, N. A., & Zaki, H. F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119865 · Cited by 21
Waller, J. A., Tamm, J. A., Abdourahman, A., Pehrson, A. L., Li, Y., Cajina, M., & Sánchez, C. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.014 · Cited by 20
Li, Y., Sánchez, C., & Gulinello, M. E. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx004 · Cited by 19
“Vortioxetine is a serotonin (5-HT) transporter (SERT) inhibitor, an agonist for 5-HT1A, a partial agonist for 5-HT1B, and an antagonist for 5-HT1B 5-HT3 and 5-HT7 receptors (Bang-Andersen et al., 2011).”
BackgroundStructural basis for partial agonism in 5-HT3A receptors
Felt, K. C., Stauffer, M., Salas-Estrada, L. A., Guzzo, P. R., Xie, D., Huang, J., Filizola, M., & Chakrapani, S. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01140-2 · Cited by 21
“However, species-specific differences in activity have been previously reported for vortioxetine and other orthosteric ligands 18,32 .”
Xue, L., Bocharova, M., Young, A. H., & Aarsland, D. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.003 · Cited by 20
Yang, Y. K., Chen, C., Tsai, C.-F., Chang, C., Lai, T.-J., Lee, C.-T., Lin, C., Lan, T., & Herr, K. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1980869 · Cited by 19
Singh, K., Bhatia, R., Kumar, B., Singh, G., & Monga, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211102154311 · Cited by 19
Thase, M. E., Jacobsen, P. L., Hanson, E., Xu, R., Tolkoff, M., & Murthy, N. V. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.002 · Cited by 18
Reddy, S., Fayyad, R., Edgar, C. J., Guico-Pabia, C. J., & Wesnes, K. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116631649 · Cited by 17
“, 2014) or the multimodal serotoninergic antidepressant vortioxetine (Bang-Andersen et al., 2011; McIntyre et al., 2014).”
BackgroundLópez-Sánchez, U., Munro, L. J., Ladefoged, L. K., Pedersen, A. J., Brun, C. C., Lyngby, S. M., Baud, D., Juillan‐Binard, C., Pedersen, M. G., Lummis, S. C. R., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01282-x · Cited by 17
Self-citationTalukdar, V., Mondal, K., Halder, P., & Das, P. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c02852 · Cited by 17
5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Andrade, R., Barnes, N. M., Baxter, G. S., Bockaert, J., Branchek, T. A., Butler, A. S., Cohen, M. L., Dumuis, A., Eglen, R. M., Göthert, M., et al. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1/2019.4 · Cited by 18
Wang, W.-T., Qian, H., Wu, J.-W., Chen, X., & Li, J. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126769 · Cited by 18
Shiroyama, T., Fukuyama, K., & Okada, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810013 · Cited by 18
“6 nM) and 5-HT7R (Ki = 200 nM), and an agonistic affinity to rat 5-HT1AR (Ki = 230 nM) [19,57,58].”
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 5
Gomółka, A., Ciesielska, A., Wróbel, M. Z., Chodkowski, A., Kleps, J., Dawidowski, M., Siwek, A., Wolak, M., Stachowicz, K., Sławińska, A., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.003 · Cited by 17
Synthesis and evaluation of cytotoxic activities of artemisinin derivatives
Sun, Q., Wang, J., Li, Y., Zhuang, J., Zhang, Q., Sun, X., & Sun, D. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13016 · Cited by 17
Ladefoged, L. K., Munro, L. J., Pedersen, A. J., Lummis, S. C. R., Bang‐Andersen, B., Balle, T., Schiøtt, B., & Kristensen, A. S. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.113530 · Cited by 19
“The antidepressant effect of vortioxetine involves its highly potent inhibition of the serotonin transporter (Andersen et al., 2009; Bang-Andersen et al., 2011).”
BackgroundMethodSelf-citation5HT6receptor antagonists: a patent update. Part 1. Sulfonyl derivatives
Ivachtchenko, A. V., & Ivanenkov, Y. A. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.709236 · Cited by 16
“During the last 5 years, a significant number of comprehensive reviews and focused book chapters which describe the medicinal chemistry profile as well as pharmacology of 5HG6R ligands has been published [8-35].”
BackgroundNackenoff, A. G., Simmler, L. D., Baganz, N. L., Pehrson, A. L., Sánchez, C., & Blakely, R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00038 · Cited by 16
Mahableshwarkar, A. R., Affinito, J., Reines, E. H., Xu, J., Nomikos, G. G., & Jacobsen, P. L. (2019) · CNS Spectrums · doi:10.1017/s109285291900097x · Cited by 17
Nissen, T. D., Laursen, B., Viardot, G., L’Hostis, P., Danjou, P., Sluth, L. B., Gram, M., Bastlund, J. F., Christensen, S. R., & Drewes, A. M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.039 · Cited by 19
11C-labeling and preliminary evaluation of vortioxetine as a PET radioligand
Andersen, V. L., Hansen, H. D., Herth, M. M., Knudsen, G. M., & Kristensen, J. L. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.044 · Cited by 16
Matsuno, K., Nakamura, K., Aritomi, Y., & Nishimura, A. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.381 · Cited by 16
Smagin, G. N., Song, D., Budac, D. P., Waller, J. A., Li, Y., Pehrson, A. L., & Sánchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.001 · Cited by 18
Daboe, M., Parlak, C., Direm, A., Alver, Ö., & Ramasami, P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2195004 · Cited by 15
“Furthermore, alosetron is clinically used to treat irritable bowel syndrome (Chey et al., 2015) and vortioxetine is one of the non-selective antidepressants which targets the serotonin transporter and receptors (Bang-Andersen et al., 2011).”
BackgroundClinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder
Christensen, M. C., McIntyre, R. S., Adair, M., Florea, I., Loft, H., & Fagiolini, A. M. (2023) · CNS Spectrums · doi:10.1017/s1092852923002249 · Cited by 15
“42,47,48 We hypothesize that the transient initial partial agonistic activity of vortioxetine at 5-HT 3 receptors may contribute to nausea and vomiting in patients who experience these adverse effects and that the timing of the shift from partial agonistic to 5-HT 3 functional antagonist activity ―…”
BackgroundSequential One-Pot (Het)arene Thioetherification and Amination with Nickel and Visible Light
Düker, J., Ghosh, I., & König, B. (2023) · ACS Catalysis · doi:10.1021/acscatal.3c03860 · Cited by 15
New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development
Heal, D. J., Gosden, J., & Smith, S. L. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_332 · Cited by 17
Vortioxetine as an analgesic in preclinical inflammatory pain models: Mechanism of action
Todorović, M. B., Micov, A. M., Nastić, K., Tomic´, M. A., Pecikoza, U. B., Vuković, M., & Stepanović-Petrović, R. M. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12737 · Cited by 17
“It could be suggested that its antinociceptive effect is mediated partly by enhancing endogenous adenosine that acts at A1 receptors, bearing in mind that there is no evidence that vortioxetine binds to adenosine receptors [6].”
BackgroundAn Investigation Into Vortioxetine Salts: Crystal Structure, Thermal Stability, and Solubilization
He, S.-F., Zhang, X.-R., Zhang, S., Guan, S., Li, J., Li, S., & Zhang, L. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.04.018 · Cited by 15
Yang, K., Stepanov, V., Amini, N., Martinsson, S., Takano, A., Bundgaard, C., Bang‐Andersen, B., Sánchez, C., Halldin, C., Farde, L., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0442-4 · Cited by 14
Self-citationCumbo, E., Adair, M., Åström, D. O., & Christensen, M. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1037816 · Cited by 17
“The mechanism of action of vortioxetine is thought to be related to both direct modulation of serotoninergic receptor activity and inhibition of the serotonin (5-HT) transporter (Bang-Andersen et al., 2011).”
BackgroundPromising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 16
Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder
Dubovsky, S. L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.904286 · Cited by 15
“In rat studies, it increases extracellular 5-HT, dopamine, histamine, acetylcholine and norepinephrine levels in the medial prefrontal cortex and ventral hippocampus [6,10].”
BackgroundPharmacological Tool Compounds for the Free Fatty Acid Receptor 4 (FFA4/GPR120)
Hansen, S. V. F., & Ulven, T. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_60 · Cited by 14
“Many drugs currently on the market are of polypharmacological nature, for example the new antidepressant vortioxetine (Bang-Andersen et al. 2011).”
BackgroundCarlo, V. D., Vismara, M. E. M., Grancini, B. M., Benatti, B., Bosi, M. F., Colombo, A., Viganò, C. A., & Dell’Osso, B. M. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2750 · Cited by 14
Kumar, B., Kumar, N., Thakur, A., Kumar, V., Kumar, R., & Kumar, V. (2022) · Current Drug Targets · doi:10.2174/1389450123666220117104038 · Cited by 14
Ragi, N., Velma, G. R., Pallerla, P., Siddiqua, S., Veeresham, A., Rachamalla, H. K., Pabbaraja, S., & Prabhakar, S. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113442 · Cited by 14
Chakroborty, S., Geisbush, T. R., Dale, E., Pehrson, A. L., Sánchez, C., & West, A. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00764 · Cited by 13
“Based on binding affinities of vortioxetine and target expression levels in the LSN (Pazos and Palacios, 1985; Pazos et al., 1985; Bang-Andersen et al., 2011; Mørk Frontiers in Pharmacology | www.frontiersin.org 6 October 2017 | Volume 8 | Article 764 FIGURE 3 | Between groups comparison of the…”
InfluentialNaik, H., Chan, S., Vakilynejad, M., Chen, G., Loft, H., Mahableshwarkar, A. R., & Areberg, J. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12513 · Cited by 15
Growing Utilization of Radical Chemistry in the Synthesis of Pharmaceuticals
Gupta, A., & Laha, J. K. (2023) · The Chemical Record · doi:10.1002/tcr.202300207 · Cited by 13
Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00027-4 · Cited by 16
N-Chlorosuccinimide promoted direct C(sp2)–H bond thiolation of the methoxybenzenes with thiophenols
Reddy, M. R., Kumar, G. S., & Meshram, H. M. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.06.126 · Cited by 13
Padovani, A., Caratozzolo, S., Benussi, A., Galli, A., Rozzini, L., Cosseddu, M., Turrone, R., & Pilotto, A. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.132 · Cited by 13
“Vortioxetine is a multimodal drug approved for major depressive disorder (MDD), functioning through serotonin (5-HT) receptor activity and 5-HT transporter inhibition (23, 24).”
Xue, L., Lewis, E. T., Bocharova, M., Young, A. H., & Aarsland, D. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.01.029 · Cited by 12
Li, T., Cui, X., Sun, L., & Li, C. (2014) · RSC Advances · doi:10.1039/c4ra04528a · Cited by 12
Fu, J., Peng, L., & Li, X. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s104050 · Cited by 12
“6 This may be the reason that vortioxetine does not significantly cause sexual dysfunction.”
Boros, Z., Nagy‐Győr, L., Kátai-Fadgyas, K., Köhegyi, I., Ling, I., Nagy, T., Iványi, Z., Oláh, M., Ruzsics, G., Temesi, O. K., et al. (2019) · Journal of Flow Chemistry · doi:10.1007/s41981-019-00036-x · Cited by 12
Aygün, H., & Ayyıldız, M. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107797 · Cited by 12
Liu, H.-L., Zhang, R.-J., Han, D., Yu, F., Luo, T.-H., & Xu, D. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c00906 · Cited by 12
He, H., Wang, W., Lyu, J., Zheng, J., Guo, L., An, X., Fan, Y., & Ma, X. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.10.018 · Cited by 13
“Vortioxetine was found to increase extracellular 5-HT more than did SSRIs and SNRIs in a rat model (Bang-Andersen et al., 2011).”
BackgroundSharp, A. M., Lertphinyowong, S., Yee, S. S., Paredes, D., Gelfond, J., Johnson‐Pais, T. L., Leach, R. J., Liss, M. A., Risinger, A. L., Sullivan, A. C., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05274-4 · Cited by 12
Vortioxetine overdose in a suicidal attempt: A case report
Mazza, M. G., Rossetti, A., Botti, R. E., & Clerici, M. (2018) · Medicine · doi:10.1097/md.0000000000010788 · Cited by 13
“The rate of binding of vortioxetine to plasma protein is 96%; vortioxetine is metabolized by P450 enzymes (especially CYP2D6) with no significant induction or inhibition of P450 and no pharmacologically inactive metabolites.([2,3]) Antidepressant properties of vortioxetine have been demonstrated by preclinical and cli…”
Yi, C., Zhu, M.-M., Ren, J., Zhu, W., Song, C., & Wu, Y. (2025) · Organic Chemistry Frontiers · doi:10.1039/d5qo01013f · Cited by 11
Peters, M. S., Park, C. H. J., Turner, A., Guerin, A. A., & Kim, J. H. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100064 · Cited by 11
Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
Miao, J., Wang, G., Hou, J., Areberg, J., Zhao, Y., Højer, A., & Ettrup, A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01092-4 · Cited by 11
“It has two different mechanisms of action: direct action at specific serotonin (5-hydroxytryptamine, 5-HT) receptors and serotonin reuptake inhibition [7].”
BackgroundJaramillo, D. N., Millán, D., & Guevara‐Pulido, J. O. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106403 · Cited by 11
Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents
Waller, J. A., Nygaard, S. H., Li, Y., du Jardin, K. G., Tamm, J. A., Abdourahman, A., Elfving, B., Pehrson, A. L., Sánchez, C., & Wernersson, R. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0376-x · Cited by 11
“In addition to acting as a 5-HT transporter (SERT) inhibitor, it is an antagonist at 5-HT1D, 5-HT3, and 5-HT7 receptors, agonist at 5-HT1A receptors, and partial agonist at 5-HT1B receptors [10, 11].”
BackgroundZheng, J., Wang, Z., & Li, E. (2019) · African Health Sciences · doi:10.4314/ahs.v19i1.48 · Cited by 12
Roberts, A., Grafton, G., Powell, A. D., Brock, K., Chen, C., Xie, D., Huang, J., Liu, S., Cooper, A. J., Brady, C., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261008 · Cited by 13
“, 2018) displays 5-HT3 receptor partial agonist actions (Bang-Andersen et al., 2011; Ladefoged et al., 2018), and a case report describes the symptomatic relief of a patient with IBSd by this drug (Aydin and Ünal-Aydin, 2017).”
BackgroundLi, J., Li, L.-Y., He, S.-F., Li, S., Dong, C., & Zhang, L. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.12.010 · Cited by 11
Kucwaj‐Brysz, K., Kurczab, R., Żesławska, E., Lubelska, A., Marć, M. A., Latacz, G., Satała, G., Nitek, W., Kieć‐Kononowicz, K., & Handzlik, J. (2018) · MedChemComm · doi:10.1039/c8md00168e · Cited by 11
On assessing potential efficacy for vortioxetine in generalized anxiety disorder
Baldwin, D. S., & Nutt, D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.018 · Cited by 11
Christensen, M. C., Cañellas, F., Loft, H., & Montejo, A. L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s473056 · Cited by 11
Zheng, J., Zhou, L., Gong, X., Yang, F., Cheng, J., Ma, R., Wu, C., Xu, Z., Zhu, W., Yang, H., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116564 · Cited by 10
Novel agents in development for the treatment of depression
Grady, M. M., & Stahl, S. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000758 · Cited by 11
Yin, J., Meng, X., Cai, C., Wang, L., & Gong, H. (2022) · Green Synthesis and Catalysis · doi:10.1016/j.gresc.2022.04.003 · Cited by 10
Sun, S., Ye, H., Mao, T., Guo, Y., Liu, H., Li, J., & Bi, X. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c02374 · Cited by 10
Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine
Chen, G., Nomikos, G. G., Affinito, J., Jacobson, W., Zhao, Z., Wang, S., & Xie, J. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.577 · Cited by 11
Mitsudo, K., Matsuo, R., Yonezawa, T., Inoue, H., Mandai, H., & Suga, S. (2020) · Angewandte Chemie · doi:10.1002/ange.202001149 · Cited by 10
d’Andrea, G., Miuli, A., Pettorruso, M., Cavallotto, C., Marrangone, C., Cocco, A., Filippis, S. D., Martiadis, V., Andriola, I., Barlati, S., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.004 · Cited by 9
Use of vortioxetine in different neurological fields: a systematic review and future perspectives
Verrienti, G., Colonna, I., & Raccagni, C. (2025) · Neurological Sciences · doi:10.1007/s10072-025-07987-1 · Cited by 9
Dai, C., Fu, Y., Li, X., Lin, M., Li, Y., Li, X., Huang, K., Zhou, C., Jian, X., Zhao, Q., et al. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2400470 · Cited by 10
Copper-catalyzed aryl ortho -C–H thiolation of aldehydes via a transient directing group strategy
Mei, M., Yi, D., Meng, F., Tang, J., & Zhang, Y. (2025) · Organic Chemistry Frontiers · doi:10.1039/d5qo00472a · Cited by 9
Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder
Malikowska‐Racia, N., Popik, P., & Sałat, K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112380 · Cited by 9
Hsiao, H., Wang, J. C.-F., & Wu, S. (2022) · Biomedicines · doi:10.3390/biomedicines10061318 · Cited by 9
“1 μM [49], although this drug showed high-affinity binding for the h5-HT3A receptor and potent functional antagonism at cloned rat and human 5-HT3A receptors [1].”
Background[Role of cAMP/CREB/BDNF signaling pathway in anti-depressive effect of vortioxetine in mice].
Yu, H., Chen, J., Zeng, B., Zhong, Q.-P., Xu, J., & Liu, Y.-G. (2017) · 南方医科大学学报 · doi:10.3969/j.issn.1673-4254.2017.01.20 · Cited by 9
Elhenawee, M., Saleh, H., Hussien, E. M., & Derar, A. R. (2020) · IEEE Sensors Journal · doi:10.1109/jsen.2020.2997738 · Cited by 9
“VORTIOXETINE hydrobromide, which is chemically known as 1-[2-(2,4-Dimethylphenylsulfanyl)-phenyl]piperazine [1], has recently been approved by the Food and Drug Administration (FDA) for the treatment of major depressive disorder, which is a medical illness with the symptoms of sadness and loss of interest in social re…”
BackgroundZuccarello, P., Carnazza, G., & Barbera, N. (2023) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15198 · Cited by 11
“It acts as a 5- HT1A receptor agonist, 5- HT3, 5- HT7, and 5- HT1D receptor antagonist, 5- HT1B receptor partial agonist, and inhibitor of the 5- HT transporter (SERT) [4, 5].”
BackgroundVortioxetine in the treatment of major depressive disorder
Baldwin, D. S., & Hanumanthaiah, V. B. (2015) · Future Neurology · doi:10.2217/fnl.14.69 · Cited by 9
Two cases of mild serotonin toxicity via 5-hydroxytryptamine 1A receptor stimulation
Nibuya, M., Nakayama, H., Umeda, S., Terao, T., Nisijima, K., & Nomura, S. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s58714 · Cited by 9
Ebrahimzadeh, M. A., Mansari, M. E., & Blier, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.036 · Cited by 11
“The RT50 values were determined as an in vivo measure for activity of 5-HTT and NET.”
BackgroundInfluentialLi, Y., Lv, Z., Wang, Y., Wan, Z., Knochel, P., & Chen, Y. (2024) · Organic Letters · doi:10.1021/acs.orglett.3c03887 · Cited by 9
Singh, P., Agrawal, P., & Singh, K. P. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115128 · Cited by 8
Propriétés pharmacologiques de la vortioxetine et leurs conséquences pré-cliniques
David, D. J. P., Tritschler, L., Guilloux, J., Gardier, A. M., Sánchez, C., & Gaillard, R. (2016) · L Encéphale · doi:10.1016/s0013-7006(16)30015-x · Cited by 10
Metadata
- Authors
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
- Affiliations
- Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-04-12
- Volume
- 54
- Issue
- 9
- Pages
- 3206-3221
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2036812642
- Cited by
- 606
- References
- 58
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.